Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Jensen Investment Adam Calamar, Kurt Havnaer, Tyra Pratt | “LH is a leading provider of diagnostic testing services in the U.S., supported by stable demand and major economies of scale. The company represents a highly defensive holding that is well-positioned to benefit from secular demographic shifts like an aging population.” | BULL | Q1 2026 Apr 29, 2026 | View Pitch |
Diamond Hill Large Cap Strategy Austin Hawley | “Shares of leading diagnostic lab Labcorp declined amid investor concern surrounding lower-than-expected guidance. The weakness was driven by delays in acquisition closings and softness in its development pipeline. These factors prompted a restructuring of that business. Despite the near-term challenges, Labcorp maintains strong competitive advantages. Its scale enables low-cost operations and better-than-average margins over time. BSD Analysis: Labcorp is diagnostics infrastructure, not a pandemic trade — even if the market forgot that. Routine testing, drug development services, and clinical trials drive recurring demand. Volume normalized post-COVID, exposing the real earnings power underneath the noise. Scale matters because payers and pharma want fewer, reliable partners. Pricing pressure exists, but cost discipline offsets it over time. The drug development segment adds countercyclical balance. This is not a high-growth healthcare name. It's medical plumbing with operating leverage. Labcorp compounds when execution is boring and volumes stay steady.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.